OBJECTIVE: To evaluate the recognition of computationally designed, centralized HIV-1 antigens derived from clade B, C and group M sequences by individuals infected with HIV-1-M clades B and C. METHODS: Three centralized sequences have been described - consensus, ancestor and center-of-tree - each of which attempts to minimize the genetic distance to circulating viruses. It is unclear whether any of these sequences affords an advantage for T cell recognition. The ability of centralized clade B and C and group M peptides to be targeted in ELISpot assays was assessed using samples from the United States, Peru, Barbados and South Africa. RESULTS: Each of the clade-specific centralized peptide sets was equally powerful in detecting cytotoxic T cell (CTL) responses. Importantly, combination of these sets detected significantly broader responses. Although broad responses were observed in populations from which few sequences informed the design of these centralized sequences, the genetic distance between local sequences and the respective test set was inversely associated with response rates. Furthermore, the CTL reactivity in clade C-infected subjects using clade B peptides was reduced relative to within-clade peptide responses, while responses to group M peptides were comparable to within-clade peptide responses in these individuals. CONCLUSIONS: All tested centralized antigens provided a similarly potent set of antigenic peptides. However, the significantly broader responses detected using the combination of sets highlight the importance of maximizing coverage of HIV-1 sequence diversity in vaccine preparations, as well as in the evaluation of CTL responses in HIV-1-infected individuals and those vaccinated.
OBJECTIVE: To evaluate the recognition of computationally designed, centralized HIV-1 antigens derived from clade B, C and group M sequences by individuals infected with HIV-1-M clades B and C. METHODS: Three centralized sequences have been described - consensus, ancestor and center-of-tree - each of which attempts to minimize the genetic distance to circulating viruses. It is unclear whether any of these sequences affords an advantage for T cell recognition. The ability of centralized clade B and C and group M peptides to be targeted in ELISpot assays was assessed using samples from the United States, Peru, Barbados and South Africa. RESULTS: Each of the clade-specific centralized peptide sets was equally powerful in detecting cytotoxic T cell (CTL) responses. Importantly, combination of these sets detected significantly broader responses. Although broad responses were observed in populations from which few sequences informed the design of these centralized sequences, the genetic distance between local sequences and the respective test set was inversely associated with response rates. Furthermore, the CTL reactivity in clade C-infected subjects using clade B peptides was reduced relative to within-clade peptide responses, while responses to group M peptides were comparable to within-clade peptide responses in these individuals. CONCLUSIONS: All tested centralized antigens provided a similarly potent set of antigenic peptides. However, the significantly broader responses detected using the combination of sets highlight the importance of maximizing coverage of HIV-1 sequence diversity in vaccine preparations, as well as in the evaluation of CTL responses in HIV-1-infected individuals and those vaccinated.
Authors: Oksana Penezina; Neil X Krueger; Isaac R Rodriguez-Chavez; Michael P Busch; John Hural; Jerome H Kim; Robert J O'Connell; Eric Hunter; Said Aboud; Keith Higgins; Victor Kovalenko; David Clapham; David Crane; Andrew E Levin Journal: Clin Vaccine Immunol Date: 2014-01-08
Authors: Zaza M Ndhlovu; Alicja Piechocka-Trocha; Seanna Vine; Ashley McMullen; Kegakilwe C Koofhethile; Phillip J R Goulder; Thumbi Ndung'u; Dan H Barouch; Bruce D Walker Journal: J Immunol Date: 2011-05-16 Impact factor: 5.422
Authors: Coral-Ann M Almeida; Steven G Roberts; Rebecca Laird; Elizabeth McKinnon; Imran Ahmad; Niamh M Keane; Abha Chopra; Carl Kadie; David Heckerman; Simon Mallal; Mina John Journal: Vaccine Date: 2010-07-07 Impact factor: 3.641
Authors: Wing-Pui Kong; Lan Wu; Timothy C Wallstrom; Will Fischer; Zhi-Yong Yang; Sung-Youl Ko; Norman L Letvin; Barton F Haynes; Beatrice H Hahn; Bette Korber; Gary J Nabel Journal: J Virol Date: 2008-12-24 Impact factor: 5.103
Authors: Christine M Rousseau; Marcus G Daniels; Jonathan M Carlson; Carl Kadie; Hayley Crawford; Andrew Prendergast; Philippa Matthews; Rebecca Payne; Morgane Rolland; Dana N Raugi; Brandon S Maust; Gerald H Learn; David C Nickle; Hoosen Coovadia; Thumbi Ndung'u; Nicole Frahm; Christian Brander; Bruce D Walker; Philip J R Goulder; Tanmoy Bhattacharya; David E Heckerman; Bette T Korber; James I Mullins Journal: J Virol Date: 2008-04-23 Impact factor: 5.103
Authors: Daniel Yerly; David Heckerman; Todd Allen; Todd J Suscovich; Nebojsa Jojic; Carl Kadie; Werner J Pichler; Andreas Cerny; Christian Brander Journal: J Immunol Date: 2008-11-01 Impact factor: 5.422